Peter Greenleaf

Peter Greenleaf

Chief Executive Officer chez AURINIA PHARMACEUTICALS INC.

Fortune : 8 M $ au 31/03/2024

54 ans
Health Technology
Commercial Services
Finance

Profil

Peter S.
Greenleaf
currently works at Aurinia Pharmaceuticals, Inc., as President, Chief Executive Officer & Director from 2019, Maryland Venture Fund, as Chairman, Revolo Biotherapeutics Ltd., as Chairman from 2020, Pharmaceutical Research & Manufacturers of America, as Director, ValenzaBio, Inc., as Director, and Petrichor Healthcare Capital Management LP, as Advisory.
Mr. Greenleaf also formerly worked at Histogenics Corp., as President, Chief Executive Officer & Director from 2013 to 2014, Sucampo Pharmaceuticals LLC, as Chairman & Chief Executive Officer from 2016 to 2018, BioDelivery Sciences International, Inc., as Chairman from 2018 to 2022, Antares Pharma, Inc., as Independent Director from 2018 to 2022, Mast Therapeutics, Inc., as Independent Director, Oldtech, Inc., as Director, Kiora Pharmaceuticals, Inc., as Director from 2018 to 2020, Biotechnology Innovation Organization, as Director, Melinta Subsidiary Corp., as Director, Tech Council of Maryland, Inc., as Director, LigoCyte Pharmaceuticals, Inc., as Director, Mirna Therapeutics, Inc., as Independent Director, Corridor Pharmaceuticals, Inc., as Director, Avalo Therapeutics, Inc., as Director from 2019 to 2020, Savara, Inc., as Director, OS Therapies, Inc., as Director, Centocor, Inc., as VP-US Gastroenterology Commercial Group, MedImmune LLC, as President from 2006 to 2013, US Healthcare, Inc., as Principal, Hallmark Cards, Inc., as Principal, MedImmune Ventures, Inc., as President from 2010 to 2013, Roche Diagnostics Corp., as Principal from 1996 to 1998, and The University of Maryland Baltimore Foundation, Inc., as Trustee.
Mr. Greenleaf received his Masters Business Admin degree from St. Joseph's University and undergraduate degree from Western Connecticut State University.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
06/03/2024 1 522 114 ( 1,05% ) 8 M $ 31/03/2024

Postes actifs de Peter Greenleaf

SociétésPosteDébut
AURINIA PHARMACEUTICALS INC. Chief Executive Officer 29/04/2019
Consultant / Advisor -
Chairman 17/12/2020
Director/Board Member -
Chairman -
Director/Board Member -
Tous les postes actifs de Peter Greenleaf

Anciens postes connus de Peter Greenleaf

SociétésPosteFin
ANTARES PHARMA, INC. Director/Board Member 24/05/2022
BIODELIVERY SCIENCES INTERNATIONAL, INC. Chairman 22/03/2022
AVALO THERAPEUTICS, INC. Chief Executive Officer 15/04/2019
░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░ ░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░
Voir l'expérience en détail de Peter Greenleaf

Formation de Peter Greenleaf

St. Joseph's University Masters Business Admin
Western Connecticut State University Undergraduate Degree

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Peter Greenleaf

Relations

99

Relations au 1er degré

31

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Sociétés cotées4
KIORA PHARMACEUTICALS, INC.

Health Technology

AVALO THERAPEUTICS, INC.

Health Technology

AURINIA PHARMACEUTICALS INC.

Health Technology

SAVARA INC.

Health Technology

Entreprise privées25

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Consumer Non-Durables

Health Technology

Health Technology

Finance

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

LigoCyte Pharmaceuticals, Inc.

Health Technology

The University of Maryland Baltimore Foundation, Inc.

Miscellaneous

Finance

Health Technology

Health Technology

Finance

Commercial Services

Health Technology

Commercial Services

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Peter Greenleaf